

NCIC CLINICAL TRIALS GROUP

MELANOMA

DISEASE SITE COMMITTEE MEETING AGENDA

THE CHELSEA HOTEL, TORONTO, ONTARIO

ROOM: SCOTT

DATE: SUNDAY MAY 3RD, 2015

TIME: 8:00 AM – 12:00 PM

CHAIRS: DR. TERESA PETRELLA, DR. ALAN SPATZ

(12:15 PM – 1:00 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

8:00 - 8:10 am	Welcome and Approval of 2014 Spring Meeting Minutes	T. Petrella
8:10 - 9:00 am	Trial Updates <ul style="list-style-type: none"> • MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG) T. Petrella • ME.12 - Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma T. Petrella • MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance) A. Joshua • IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases T. Petrella • ME11 - Adjuvant Pegylated-Interferon-alpha2b (Sylatron™) for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group A. Spatz 	
9:00 - 10:00 am	New Proposals <ul style="list-style-type: none"> • A phase III randomized trial comparing high dose interferon alpha-2b to MK-3475 (pembrolizumab) in patients with high risk resected melanoma - SWOG S1404 T. Petrella • Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma - ECOG EA6141 T. Petrella 	

9:00 - 10:00 am	New Proposals Continued	
	<ul style="list-style-type: none"> • Autoantibodies against immune checkpoints: a putative mechanism to account for long term survival following spontaneous regression of metastatic melanoma • Translational proposal • Assessment of response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker • Adjuvant mucosal melanoma trial • Neoadjuvant proposal 	<p>C. Lee</p> <p>A. Spatz</p> <p>T. Petrella</p> <p>T. Petrella</p> <p>X. Song</p>
10:00 - 10:15 am	Break	
10:15 - 11:00 am	New Proposals Continued	
	<ul style="list-style-type: none"> • Reolysin and Immune Checkpoint Inhibitors: Rational for the Combination • Reolysin Proposal in Melanoma 	<p>G. Selvaggi</p> <p>J. Monzon</p>
11:00 - 12:00 pm	Melanoma Site Strategic Planning <i>(NCIC CTG Members Only)</i>	
	<ul style="list-style-type: none"> • Background • Discussion 	<p>J. Dancey</p> <p>T. Petrella</p>
12:00 pm	Meeting Adjourned	
12:15 - 1:00 pm	<i>Executive Committee meeting to follow (closed)</i>	